Biovail Plans Phase III Studies Of Sexual Dysfunction Candidate In 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Licensing deal for the product is one of several Biovail intends to enter into to bolster its pipeline.
You may also be interested in...
More Depressing News For Biovail: Decision On New Wellbutrin Formula Six Months Away
Agency has designated Biovail’s complete response to a “not approvable” letter as a class 2 review, giving application an April 23, 2008, action date, as opposed to a class 1 review, which would take only two months.
More Depressing News For Biovail: Decision On New Wellbutrin Formula Six Months Away
Agency has designated Biovail’s complete response to a “not approvable” letter as a class 2 review, giving application an April 23, 2008, action date, as opposed to a class 1 review, which would take only two months.
Biovail NDA For New Wellbutrin Formulation Is “Not Approvable”
FDA had concerns over design of pharmacokinetic studies of once-daily salt formulation of bupropion for depression, the firm says.